AusPAR: Cabotegravir sodium and cabotegravir/rilpivirine

Australian Public Assessment Report

AusPAR

AusPAR: Cabotegravir sodium and cabotegravir/rilpivirine [PDF, 1.46 MB]

AusPAR: Cabotegravir sodium and cabotegravir/rilpivirine [Word, 2.17 MB]

Attachment 1: Product Information for Cabotegravir sodium and cabotegravir/rilpivirine [PDF, 436.68 KB]

Attachment 1: Product Information for Cabotegravir sodium and cabotegravir/rilpivirine [Word, 170.35 KB]

Attachment 2: Product Information for Cabotegravir sodium and cabotegravir/rilpivirine [PDF, 511.51 KB]

Attachment 2: Product Information for Cabotegravir sodium and cabotegravir/rilpivirine [Word, 134.11 KB]

Device/Product Name

Vocabria and Cabenuva

Active ingredients

Cabotegravir sodium and cabotegravir/rilpivirine

AusPAR Date

3 May 2021

Published

19 May 2021

Submission Number

PM-2019-04281-1-2 and PM-2019-04280-1-2

Submission Type

New chemical entity and New fixed dose combination

Decision

Both approved